Maria G. Anelli

Bari, 70121, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Turning the Tide against Herpes Zoster in Rheumatoid Arthritis Patients Treated with JAK Inhibitors.

Turning the Tide against Herpes Zoster in Rheumatoid Arthritis Patients Treated with JAK Inhibitors.

Journal: Journal of clinical medicine

Published: June 18, 2024

Management of pregnancy in autoimmune rheumatic diseases: maternal disease course, gestational and neonatal outcomes and use of medications in the prospectiveItalian P-RHEUM.it study.

Management of pregnancy in autoimmune rheumatic diseases: maternal disease course, gestational and neonatal outcomes and use of medications in the prospectiveItalian P-RHEUM.it study.

Journal: RMD open

Published: January 08, 2024

Real-world effectiveness and persistence of golimumab as second-line anti-TNFα drug in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis patients in Italy: GO-BEYOND, a 12-month prospective observational study.

Real-world effectiveness and persistence of golimumab as second-line anti-TNFα drug in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis patients in Italy: GO-BEYOND, a 12-month prospective observational study.

Journal: International journal of rheumatic diseases

Published: November 08, 2023

Disease activity assessment for juvenile idiopathic arthritis in transitional care.

Disease activity assessment for juvenile idiopathic arthritis in transitional care.

Journal: Reumatismo

Published: August 22, 2023

Effectiveness of Golimumab as Second Anti-TNFα Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study.

Effectiveness of Golimumab as Second Anti-TNFα Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study.

Journal: Journal of clinical medicine

Published: June 24, 2022

High disease relapse after bDMARD spacing in psoriatic arthritis compared to rheumatoid arthritis and axial spondyloarthritis patients: real-life data from BIOPURE registry.

High disease relapse after bDMARD spacing in psoriatic arthritis compared to rheumatoid arthritis and axial spondyloarthritis patients: real-life data from BIOPURE registry.

Journal: Clinical rheumatology

Published: January 08, 2021

The Impact of Biologic Drugs on High-Density Lipoprotein Cholesterol Efflux Capacity in Rheumatoid Arthritis Patients.

The Impact of Biologic Drugs on High-Density Lipoprotein Cholesterol Efflux Capacity in Rheumatoid Arthritis Patients.

Journal: Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases

Published: January 04, 2021

Sarcopenia in Patients with Rheumatic Diseases: Prevalence and Associated Risk Factors.

Sarcopenia in Patients with Rheumatic Diseases: Prevalence and Associated Risk Factors.

Journal: Journal of clinical medicine

Published: November 15, 2018

Tomographic regression of pulmonary rheumatoid nodules under baricitinib therapy.

Tomographic regression of pulmonary rheumatoid nodules under baricitinib therapy.

Journal: Rheumatology (Oxford, England)

Published: September 14, 2018

Temporomandibular Disorders and Oral Features in Early Rheumatoid Arthritis Patients: An Observational Study.

Temporomandibular Disorders and Oral Features in Early Rheumatoid Arthritis Patients: An Observational Study.

Journal: International journal of medical sciences

Published: July 07, 2018

Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment.

Lipids and Atherogenic Indices Fluctuation in Rheumatoid Arthritis Patients on Long-Term Tocilizumab Treatment.

Journal: Mediators of inflammation

Published: May 05, 2018

Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.

Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.

Journal: Seminars in arthritis and rheumatism

Published: October 23, 2016

Showing 1-12 of 23

Last Updated: 09/26/2026